Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed

Madrigal ((MDGL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Madrigal’s latest earnings call struck an upbeat tone, highlighting powerful commercial traction for Rezdiffra and growing scientific momentum, even as management acknowledged higher spending, royalty drag and delayed profitability. Executives framed today’s margin pressure and cash drawdown as deliberate investments ahead of pivotal clinical readouts they expect will unlock much larger long‑term value.

Blockbuster Sales Cement Rezdiffra’s Commercial Breakout

Rezdiffra has now passed the blockbuster threshold, with trailing 12‑month net sales topping $1.1 billion and underscoring strong market demand. First‑quarter 2026 net sales reached $311.3 million, up 127% year over year, confirming that revenue growth remains firmly in hyper‑growth territory despite intensifying competition and discounting.

Patient Growth Surges as Addressable Market Widens

Active patients on Rezdiffra climbed to more than 42,250 by quarter end, roughly 2.5 times the level a year earlier, showing rapid adoption in clinical practice. The U.S. diagnosed F2/F3 population has expanded from about 315,000 at the end of 2023 to roughly 460,000 by the end of 2025, suggesting a nearly 50% increase in the company’s core addressable market.

Pipeline Broadens with siRNA Asset and >10 Programs

Madrigal now counts more than 10 programs in its pipeline, highlighted by the in‑licensing of ARO‑PNPLA3, a clinical‑stage siRNA targeting a genetically defined subgroup. In Phase I testing, ARO‑PNPLA3 delivered up to a 46% reduction in liver fat at 12 weeks following a single dose in PNPLA3 homozygous patients, a group representing about 30% of F2–F3 cases.

Outcomes Trials Advance Toward 2027–2028 Catalysts

The company is running an event‑driven F4C outcomes trial for Rezdiffra with a data readout expected in 2027, a key step toward broader outcomes‑based labeling and usage. A separate histology‑driven Phase III in F2/F3 patients is slated to read out in 2028, and open‑label data showing 65% of CSPH patients shifting to lower‑risk categories by year two supports the rationale for the F4C program.

Commercial Execution, Prescriber Depth and Real‑World Proof

More than 10,000 prescribers have now written Rezdiffra, backed by established first‑line payer access that reduces friction for new starts and refills. Management highlighted its best MBRx week and best NBRx month since launch, strong real‑world data across multiple liver and lipid endpoints, and more than 40 Rezdiffra abstracts presented at scientific meetings.

Balance Sheet Resources Underpin Growth Strategy

Madrigal ended the quarter with $817.9 million in cash, cash equivalents, restricted cash and marketable securities, which management says is sufficient to fund launch and key pipeline priorities. That cash cushion also supports ongoing business development efforts, including the ARO‑PNPLA3 deal, giving the company flexibility to add complementary assets without near‑term financing.

Net Loss Highlights Near‑Term Profitability Trade‑Off

The company posted a first‑quarter 2026 net loss of $94.4 million, compared with $73.2 million a year ago, an increase of about 29% as operating expenses climbed. The loss includes $54.3 million of one‑time upfront business development costs, and management reiterated that they do not expect to be profitable in 2026, targeting profitability only in later years as revenue scales.

Operating Expenses Climb with BD and Commercial Build‑Out

Research and development expense rose to $108.7 million from $44.2 million, up roughly 146% year over year, largely driven by one‑time upfront business development spending. Selling, general and administrative costs increased to $268.5 million from $167.9 million, about 60% growth, reflecting expanded endocrinology field forces, broader direct‑to‑consumer efforts and higher marketing outlays.

Cost of Sales and Royalty Burden Pressure Margins

Cost of sales jumped to $26.8 million from $4.5 million a year earlier, a roughly 495% increase that management attributed mainly to royalties owed to Roche. This rising royalty burden is compressing gross margins even as topline revenue accelerates, adding another headwind to the company’s path to near‑term profitability.

Gross‑to‑Net Discounts Temper Reported Revenue

Madrigal now expects gross‑to‑net discounts to remain in the mid‑ to high‑30% range through the rest of 2026, weighing on realized net revenue relative to gross sales. These discounts, driven by payer dynamics and access agreements, will also dampen margins even as volumes grow, making cost discipline and efficiency increasingly important for earnings leverage.

Cash Decline Reflects Strategic Capital Deployment

Cash and equivalents fell to $817.9 million from $988.6 million at the end of 2025, a decrease of about 17%, as the company deployed capital into pipeline and supply. Management pointed to one‑time business development payments and timing of active pharmaceutical ingredient purchases as the primary factors behind the cash burn, framing it as investment in future growth and inventory.

Early‑Stage Market Leaves Ample Room for Penetration

Despite the growing diagnosed F2/F3 pool, the diagnosis rate remains just over 10%, underscoring how early the market is in terms of disease awareness and screening. Rezdiffra’s penetration is just under 10% of the 460,000 addressable patients, which management views as a significant long‑term upside opportunity but also a near‑term execution test to drive broader diagnosis and uptake.

Multi‑Year Clinical Readouts Create Execution Risk

Investors must also weigh clinical and timing risks, as key outcomes and histology data will not arrive until 2027 and 2028, respectively, leaving a long runway of uncertainty. Event rates, patient enrichment strategies and final trial outcomes will materially influence Rezdiffra’s indication expansion and peak sales, making trial execution a central risk factor over the next few years.

Guidance Underscores Growth, Investment and Delayed Profits

Management reiterated 2026 growth and financial guidance, pointing to first‑quarter net sales of $311.3 million, more than $1.1 billion in trailing 12‑month sales and over 42,250 active patients, with expectations for steady patient adds through the year. They guided to gross‑to‑net discounts in the mid‑ to high‑30% range, R&D roughly flat with 2025, higher full‑year SG&A with a second‑quarter spike, a Q2 recording of the $25 million ARO‑PNPLA3 upfront and no profitability in 2026, although they characterized future profitability as inevitable.

Madrigal’s earnings call painted a picture of a company trading near‑term margin and cash for scale, data and pipeline breadth, with Rezdiffra already delivering blockbuster revenue. For investors, the story now hinges on continued patient growth, disciplined spending and successful execution of long‑dated outcomes trials that could transform today’s early leadership into a durable franchise.